Only Face Mask Proven to Continuously Kill Bacteria and Provide Superior
Filtration to N95 Masks
Preparing for Broad Spectrum Protection in a Public Health Emergency
VANCOUVER, Sept. 4 /CNW/ - Nexera Medical, Ltd., developer, manufacturer
and distributor of antimicrobial textile products worldwide, announced today
that it has been granted a Medical Device Establishment License by Health
Canada for distribution of the SpectraShield(TM) 9900 respirator mask.
SpectraShield(TM) 9900 is the only N99 face mask proven to continuously kill
bacteria and fight microorganism contamination with filtration superior to N95
masks. Now available in Canada, the SpectraShield(TM) 9900 is intended to be
used as a front line defense against infectious and contagious diseases.
"The approval of SpectraShield(TM) 9900 in Canada marks a significant
milestone for our company, and we look forward to supplying healthcare
organizations, government agencies, first-responders and the public with this
superior product," said Marci Haas, President and Chief Executive Officer of
Nexera Medical, Inc. "We believe there are no other face masks today that are
approved to provide 'dual-action', broad-spectrum protection which may be
critical in the event of a major public health crisis in Canada. We will
continue to enhance our product portfolio to meet the needs of a growing
demand for bio-protection products."
Independent studies were conducted at Nelson Laboratories and the
University of Arizona under the guidance of Charles P. Gerba, Ph.D.,
Department of Soil, Water and Environmental Science.
"Results from the studies showed that SpectraShield(TM) 9900 respirator
mask inactivates a broad spectrum of bacteria capable of airborne transmission
to levels below detection within one hour, and in some instances less than 10
minutes, and also exhibits anti-viral activity," said Dr. Gerba.
With tested filtration performance equivalent to an N99 (meaning 99% of
contaminants are trapped in the filter and do not penetrate the mask), the
SpectraShield(TM) 9900 mask exceeds the United States Center for Disease
Control and World Health Organization guidelines for protection against
infectious microbial threats such as Avian Influenza, SARS and Tuberculosis.
Studies, conducted over the past year, were designed to evaluate the
mask's antimicrobial properties on a number of bacterial microorganisms
including Escherichia coli, streptococcus pyogenes, methicillin resistant
staphylococcus aureus, legionella pneumophila, haemophilus influenza, and
coliphage MS-2. Varying inoculation concentrations of 0 to 1,000,000 units
were tested within a time span of 0 - 60 minutes. Results indicated that 99.99
to 99.999% (or to five log reduction) of the bacterial microorganisms were
killed within one hour. More extensive evaluation studies are also underway
for viral microorganisms.
SpectraShield(TM) 9900 is manufactured using a patented technology;
antimicrobial fibers used in the mask incorporate a non-toxic silver-copper
agent proven safe for extended contact with individuals. Due to
SpectraShield(TM) 9900's antimicrobial properties, odor caused by bacterial
growth is also eliminated.
While SpectraShield(TM) 9900 is approved in Canada for commercialization,
currently Nexera Medical, Inc. is in the process of applying for regulatory
approvals in other markets including the United States, European Union,
Australia and Japan. Nexera Medical Inc. has already taken orders in several
other countries around the world.
About Nexera Medical Ltd.
Nexera Medical Ltd., a wholly owned subsidiary of Nexera Medical Inc., is
engaged in the development, manufacturing and distribution of antimicrobial
respirator and surgical masks, as well as other antimicrobial textile based
medical products such as medical slings, surgical site aprons and hospital
linen products worldwide. Headquartered in Fort Lauderdale, Florida, the
company's mission is to create high-quality, cutting-edge health related
medical products designed to safeguard and enhance the quality of human life.
All of Nexera's products are designed to provide maximum protection against
microorganisms such as bacteria, virus and fungus using Fosshield(R) patented
technology. Nexera partners with governments and leaders in the health care
industry in the fight against viral pandemic and other healthcare crises. For
more information, visit www.nexeramed.com.
SpectraShield(TM) 9900 is a registered trademark of Nexera Medical, Inc.
For further information:
For further information: Company: Stephen Mader, Nexera Medical, Inc.,
Number: (954) 495-2034, Email: email@example.com; Media: Mike Beyer, Sam
Brown Communications, (312) 961 2502, firstname.lastname@example.org